Separate terms with OR to return results that match either term.
 
Clear All
10,000 Matching Results — Export these results
Click column titles once to sort ascending, and twice to sort descending.
Show Entries
NDC-11 (Package) NDC-9 (Product) Generic Name Brand Name Strength (Descending) SEER*Rx Category Major Class Minor Class Administration Route Package Effective Date Package Discontinuation Date Status
59923-0709-05 59923-0709 temozolomide TEMOZOLOMIDE 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Jan. 25, 2019 In Use
59923-0710-14 59923-0710 temozolomide TEMOZOLOMIDE 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Jan. 25, 2019 In Use
62559-0923-14 62559-0923 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 16, 2020 Feb. 28, 2023 No Longer Used
62559-0923-51 62559-0923 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 16, 2020 Feb. 28, 2023 No Longer Used
23155-0777-71 23155-0777 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 June 15, 2022 No Longer Used
23155-0777-72 23155-0777 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral June 15, 2022 June 15, 2022 No Longer Used
64980-0336-05 64980-0336 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 17, 2017 In Use
64980-0336-14 64980-0336 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral March 17, 2017 In Use
60505-3817-03 60505-3817 Dasatinib Dasatinib 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
66993-0238-30 66993-0238 Dasatinib Dasatinib 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 3, 2024 In Use
83858-0106-30 83858-0106 Dasatinib PHYRAGO 140.0 mg/1 Chemotherapy Tyrosine Kinase Inhibitor BCR-ABL Oral Sept. 1, 2024 In Use
00085-1425-01 00085-1425 Temozolomide Temodar 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 Oct. 22, 2014 In Use
00085-1425-02 00085-1425 Temozolomide Temodar 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 Oct. 22, 2014 In Use
00085-1425-03 00085-1425 Temozolomide Temodar 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1425-04 00085-1425 Temozolomide Temodar 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Aug. 11, 1999 In Use
00085-1425-05 00085-1425 Temozolomide Temodar 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Nov. 2, 2012 In Use
62175-0243-19 62175-0243 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Feb. 10, 2016 In Use
62175-0243-24 62175-0243 Temozolomide Temozolomide 140.0 mg/1 Chemotherapy Alkylating Agent Tetrazine Oral Feb. 10, 2016 In Use
00013-0132-02 00013-0132 Estramustine Phosphate Sodium Emcyt 140.0 mg/1 Chemotherapy Alkylating Agent Nitrogen Mustard Oral Jan. 1, 1992 Sept. 30, 2024 In Use
00004-0360-09 00004-0360 Peginterferon alfa-2a Pegasys 135.0 ug/.5mL Immunotherapy Cytokine Interferon Subcutaneous Nov. 1, 2011 Feb. 8, 2018 No Longer Used
00004-0360-30 00004-0360 Peginterferon alfa-2a Pegasys 135.0 ug/.5mL Immunotherapy Cytokine Interferon Subcutaneous Nov. 1, 2011 Jan. 31, 2019 No Longer Used
47426-0201-01 47426-0201 aprepitant CINVANTI 130.0 mg/18mL Ancillary Therapy Antiemetic Substance P/Neurokinin 1 Intravenous Jan. 3, 2018 In Use
50881-0028-01 50881-0028 Pemigatinib PEMAZYRE 13.5 mg/1 Chemotherapy Tyrosine Kinase Inhibitor FGFR1, FGFR2, FGFR3 Oral April 17, 2020 In Use
76961-0101-01 76961-0101 Eflapegrastim-xnst Rolvedon 13.2 mg/.6mL Ancillary Therapy Immunostimulant Granulocyte colony stimulating factor Subcutaneous Oct. 18, 2022 In Use
55150-0311-00 55150-0311 Hydroxyprogesterone Caproate Hydroxyprogesterone Caproate 1250.0 mg/5mL Hormonal Therapy Progestin Intramuscular May 9, 2019 Oct. 9, 2019 In Use

Found 10,000 results in 12 milliseconds — Export these results